Skip to main content
. 2023 Apr 26;4(4):276–293. doi: 10.1158/2643-3230.BCD-22-0205

Figure 5.

Figure 5. Time-of-flight mass cytometry (CyTOF) identifies cellular pathways associated with divergent CD34+ populations. A and B, CyTOF of a patient with ND-AML (accession #20) who attained morphologic remission but remained MRD-positive and developed morphologic relapse following cycle 23. PCA clustering of CyTOF performed in remission (end of cycle 7) identified an expanding CD34+ cell population with increased MCL-1 levels. C and D, CyTOF of a patient with ND-AML (accession #27) with an ongoing response following 18 cycles of treatment. In contrast to the previous patient, PCA clustering of CyTOF performed at the end of cycle 3 identified marked reductions in CD34+ cell populations with increased BCL-2 levels relative to BCL-xL or MCL-1. NA, not applicable.

Time-of-flight mass cytometry (CyTOF) identifies cellular pathways associated with divergent CD34+ populations. A and B, CyTOF of a patient with ND-AML (accession #20) who attained morphologic remission but remained MRD-positive and developed morphologic relapse following cycle 23. PCA clustering of CyTOF performed in remission (end of cycle 7) identified an expanding CD34+ cell population with increased MCL-1 levels. C and D, CyTOF of a patient with ND-AML (accession #27) with an ongoing response following 18 cycles of treatment. In contrast to the previous patient, PCA clustering of CyTOF performed at the end of cycle 3 identified marked reductions in CD34+ cell populations with increased BCL-2 levels relative to BCL-xL or MCL-1. NA, not applicable.